Scholar Rock Holding Corp (SRRK) reported a Q3 2025 loss of $0.90 per share, falling short of Wall Street's consensus estimate of $-0.86. Revenue remained at $0.0 billion, matching expectations but indicating a lack of growth.
The results highlight ongoing challenges for the biopharmaceutical company, which focuses on advancing treatments for neuromuscular diseases and other serious conditions. Scholar Rock's proprietary platform aims to develop monoclonal antibodies targeting latent growth factors, with notable candidates including apitegromab, a potential therapy for spinal muscular atrophy (SMA).
The company will host an earnings conference call to discuss these results and provide further insights into its operational performance. Investors are encouraged to review the full earnings release for a comprehensive understanding of the quarter's performance and future outlook.
As of November 8, 2025, Scholar Rock has a market capitalization of $2.7 billion and a trailing twelve-month EPS of $-2.92. Upcoming earnings are scheduled for August 4, 2026, with analysts estimating an EPS of $-0.67 and revenue of $28.2 million.